Glimepiride
💊 Brand Formulations & Prices
98 brands sorted by unit price
Adglim
Diavir
Gifon
Limerid
Limep
Stimulin
Gipid
Glisulin
Limpet
Condia
Adglim
Dactus
Diavir
Gifon
Glucorid
Limerid
Sucorid
Limep
Stimulin
Sulforid
Senride
Dialon
Diaryl
Dieta
Glemep
Glimirid
Glimitus
Glims
Glirid
Gluconor
Glutim
Glymax
Leride
Limaryl
Losucon
Pride
SB-Glim
Secrin
Temglip
Gipid
Amynil
Amaryl
Glisulin
Glucorid
Limpet
Senride
Dactus
Glims
Condia
Glims
Diaryl
Dieta
Glemep
Glimitus
Glims
Glirid
Gluconor
Limaryl
Limpet
Losucon
Pride
SB-Glim
Sulforid
Sulforid
Temglip
Condia
Dactus
Dialon
Glymax
Secrin
Limpet
Dialon
Diaryl
Dieta
Glimirid
Glimirid
Glimitus
Glymax
Limaryl
Losucon
Pride
Pride
SB-Glim
Secrin
Amynil
Amaryl
Sulforid
Dieta
Glemep
Glimirid
Glimitus
Glymax
Limaryl
Losucon
SB-Glim
Secrin
Amaryl
Amaryl
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesAdglim tablet is indicated in following conditions-
Adglim is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled by diet and exercise alone.
... Read more
Adglim tablet is indicated in following conditions-
Adglim is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled by diet and exercise alone.
Adglim may be used concomitantly with metformin when diet, exercise, and Adglim or metformin alone does not result in adequate glycaemic control.
Adglim is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycaemia cannot be controlled by diet and exercise in conjunction with an oral hypoglycaemic agent.
Combined use of Adglim and insulin may increase the potential for hypoglycaemia.
Glimepiride is not suitable for the treatment of insulin dependent (type I) diabetes mellitus, or for the treatment of diabetic ketoacidosis, nor for the treatment of diabetic coma. Glimepiride must not be used in patients hypersensitive to Glimepiride, other sulfonylureas, other sulfonamides, severe hepatic dysfunction, severe impairment of renal function and dialysis patients.
Hypoglycaemia, temporary visual impairment, nausea, vomiting, diarrhoea, abdominal pain, urticaria, fall in blood pressure.
in the initial weeks of treatment, the risk of hypoglycaemia may be increased and necessitates careful monitoring. If such risk present it may be necessary to adjust the dosage of Adglim, Hypoglycaemia can almost be promptly controlled by immediate intake of carbohydrates (glucose or sugar).
Glimepiride is a sulfonylurea antidiabetic agent which decreases blood glucose concentration. The primary mechanism of action of Glimepiride appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. Glimepiride acts in concert with glucose by improving the sensitivity of beta cells to physiological glucose stimulus, resulting in insulin secretion. In addition, extrapancreatic effects like reduction of basal hepatic glucose production, increased peripheral tissue sensitivity to insulin and glucose uptake may also play role in the activity of Glimepiride. In non-fasting diabetic patients, the hypoglycaemic action of a single dose of Glimepiride persists for 24 hours.